<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 20:05:42 -0700</creation_date>
  <update_date>2013-01-15 20:05:42 -0700</update_date>
  <accession>HMDBP08048</accession>
  <secondary_accessions>
    <accession>13759</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>Tubulin beta-5 chain</synonym>
  </synonyms>
  <gene_name>TUBB</gene_name>
  <general_function>Involved in structural molecule activity</general_function>
  <specific_function>Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha-chain</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00464</accession>
      <name>Calcium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01273</accession>
      <name>Guanosine triphosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14505</accession>
      <name>Vinorelbine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14681</accession>
      <name>Vincristine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14710</accession>
      <name>Vinblastine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15310</accession>
      <name>Podofilox</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15466</accession>
      <name>Colchicine</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, acting on acid anhydrides</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>pyrophosphatase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleoside-triphosphatase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>gtpase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>purine nucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>guanyl nucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>guanyl ribonucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>gtp binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>structural molecule activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular component organization or biogenesis</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular component organization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular component assembly</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>macromolecular complex assembly</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>protein complex assembly</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular protein complex assembly</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>protein polymerization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>microtubule-based process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>microtubule-based movement</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>macromolecular complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>protein complex</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>microtubule</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cytoplasmic</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:6</chromosome_location>
    <locus>6p21.33</locus>
    <gene_sequence>&gt;1335 bp
ATGAGGGAAATCGTGCACATCCAGGCTGGTCAGTGTGGCAACCAGATCGGTGCCAAGTTC
TGGGAGGTGATCAGTGATGAACATGGCATCGACCCCACCGGCACCTACCACGGGGACAGC
GACCTGCAGCTGGACCGCATCTCTGTGTACTACAATGAAGCCACAGGTGGCAAATATGTT
CCTCGTGCCATCCTGGTGGATCTAGAACCTGGGACCATGGACTCTGTTCGCTCAGGTCCT
TTTGGCCAGATCTTTAGACCAGACAACTTTGTATTTGGTCAGTCTGGGGCAGGTAACAAC
TGGGCCAAAGGCCACTACACAGAGGGCGCCGAGCTGGTTGATTCTGTCCTGGATGTGGTA
CGGAAGGAGGCAGAGAGCTGTGACTGCCTGCAGGGCTTCCAGCTGACCCACTCACTGGGC
GGGGGCACAGGCTCTGGAATGGGCACTCTCCTTATCAGCAAGATCCGAGAAGAATACCCT
GATCGCATCATGAATACCTTCAGTGTGGTGCCTTCACCCAAAGTGTCTGACACCGTGGTC
GAGCCCTACAATGCCACCCTCTCCGTCCATCAGTTGGTAGAGAATACTGATGAGACCTAT
TGCATTGACAACGAGGCCCTCTATGATATCTGCTTCCGCACTCTGAAGCTGACCACACCA
ACCTACGGGGATCTGAACCACCTTGTCTCAGCCACCATGAGTGGTGTCACCACCTGCCTC
CGTTTCCCTGGCCAGCTCAATGCTGACCTCCGCAAGTTGGCAGTCAACATGGTCCCCTTC
CCACGTCTCCATTTCTTTATGCCTGGCTTTGCCCCTCTCACCAGCCGTGGAAGCCAGCAG
TATCGAGCTCTCACAGTGCCGGAACTCACCCAGCAGGTCTTCGATGCCAAGAACATGATG
GCTGCCTGTGACCCCCGCCACGGCCGATACCTCACCGTGGCTGCTGTCTTCCGTGGTCGG
ATGTCCATGAAGGAGGTCGATGAGCAGATGCTTAACGTGCAGAACAAGAACAGCAGCTAC
TTTGTGGAATGGATCCCCAACAATGTCAAGACAGCCGTCTGTGACATCCCACCTCGTGGC
CTCAAGATGGCAGTCACCTTCATTGGCAATAGCACAGCCATCCAGGAGCTCTTCAAGCGC
ATCTCGGAGCAGTTCACTGCCATGTTCCGCCGGAAGGCCTTCCTCCACTGGTACACAGGC
GAGGGCATGGACGAGATGGAGTTCACCGAGGCTGAGAGCAACATGAACGACCTCGTCTCT
GAGTATCAGCAGTACCAGGATGCCACCGCAGAAGAGGAGGAGGATTTCGGTGAGGAGGCC
GAAGAGGAGGCCTAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>444</residue_number>
    <molecular_weight>49670.5</molecular_weight>
    <theoretical_pi>4.52</theoretical_pi>
    <pfams>
      <pfam>
        <name>Tubulin</name>
        <pfam_id>PF00091</pfam_id>
      </pfam>
      <pfam>
        <name>Tubulin_C</name>
        <pfam_id>PF03953</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>None</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Tubulin beta chain
MREIVHIQAGQCGNQIGAKFWEVISDEHGIDPTGTYHGDSDLQLDRISVYYNEATGGKYV
PRAILVDLEPGTMDSVRSGPFGQIFRPDNFVFGQSGAGNNWAKGHYTEGAELVDSVLDVV
RKEAESCDCLQGFQLTHSLGGGTGSGMGTLLISKIREEYPDRIMNTFSVVPSPKVSDTVV
EPYNATLSVHQLVENTDETYCIDNEALYDICFRTLKLTTPTYGDLNHLVSATMSGVTTCL
RFPGQLNADLRKLAVNMVPFPRLHFFMPGFAPLTSRGSQQYRALTVPELTQQVFDAKNMM
AACDPRHGRYLTVAAVFRGRMSMKEVDEQMLNVQNKNSSYFVEWIPNNVKTAVCDIPPRG
LKMAVTFIGNSTAIQELFKRISEQFTAMFRRKAFLHWYTGEGMDEMEFTEAESNMNDLVS
EYQQYQDATAEEEEDFGEEAEEEA</protein_sequence>
  </protein_properties>
  <genbank_protein_id/>
  <uniprot_id>P07437</uniprot_id>
  <uniprot_name>TBB5_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1SA1</pdb_id>
  </pdb_ids>
  <genbank_gene_id>AF141349</genbank_gene_id>
  <genecard_id>TUBB</genecard_id>
  <geneatlas_id>TUBB</geneatlas_id>
  <hgnc_id>HGNC:20778</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Lee MG, Lewis SA, Wilde CD, Cowan NJ: Evolutionary history of a multigene family: an expressed human beta-tubulin gene and three processed pseudogenes. Cell. 1983 Jun;33(2):477-87.</reference_text>
      <pubmed_id>6688039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hall JL, Dudley L, Dobner PR, Lewis SA, Cowan NJ: Identification of two human beta-tubulin isotypes.  Mol Cell Biol. 1983 May;3(5):854-62.</reference_text>
      <pubmed_id>6865944</pubmed_id>
    </reference>
    <reference>
      <reference_text>Crabtree DV, Ojima I, Geng X, Adler AJ: Tubulins in the primate retina: evidence that xanthophylls may be endogenous ligands for the paclitaxel-binding site. Bioorg Med Chem. 2001 Aug;9(8):1967-76.</reference_text>
      <pubmed_id>11504633</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, Zhang H, Zha XM, Polakiewicz RD, Comb MJ: Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.  Nat Biotechnol. 2005 Jan;23(1):94-101. Epub 2004 Dec 12.</reference_text>
      <pubmed_id>15592455</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wang B, Malik R, Nigg EA, Korner R: Evaluation of the low-specificity protease elastase for large-scale phosphoproteome analysis. Anal Chem. 2008 Dec 15;80(24):9526-33.</reference_text>
      <pubmed_id>19007248</pubmed_id>
    </reference>
    <reference>
      <reference_text>Meierhofer D, Wang X, Huang L, Kaiser P: Quantitative analysis of global ubiquitination in HeLa cells by mass spectrometry. J Proteome Res. 2008 Oct;7(10):4566-76. Epub 2008 Sep 10.</reference_text>
      <pubmed_id>18781797</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rogowski K, Juge F, van Dijk J, Wloga D, Strub JM, Levilliers N, Thomas D, Bre MH, Van Dorsselaer A, Gaertig J, Janke C: Evolutionary divergence of enzymatic mechanisms for posttranslational polyglycylation. Cell. 2009 Jun 12;137(6):1076-87.</reference_text>
      <pubmed_id>19524510</pubmed_id>
    </reference>
    <reference>
      <reference_text>Heibeck TH, Ding SJ, Opresko LK, Zhao R, Schepmoes AA, Yang F, Tolmachev AV, Monroe ME, Camp DG 2nd, Smith RD, Wiley HS, Qian WJ: An extensive survey of tyrosine phosphorylation revealing new sites in human mammary epithelial cells. J Proteome Res. 2009 Aug;8(8):3852-61.</reference_text>
      <pubmed_id>19534553</pubmed_id>
    </reference>
    <reference>
      <reference_text>Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009 Aug 14;325(5942):834-40. Epub 2009 Jul 16.</reference_text>
      <pubmed_id>19608861</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Vinorelbine</name>
        <accession>HMDB14505</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinorelbine</name>
        <accession>HMDB14505</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinorelbine</name>
        <accession>HMDB14505</accession>
      </metabolite>
      <reference>
        <reference_text>Kruczynski A, Barret JM, Etievant C, Colpaert F, Fahy J, Hill BT: Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol. 1998 Mar 1;55(5):635-48.</reference_text>
        <pubmed_id>9515574</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinorelbine</name>
        <accession>HMDB14505</accession>
      </metabolite>
      <reference>
        <reference_text>Chang AY, Garrow GC: Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer. Semin Oncol. 1995 Apr;22(2 Suppl 5):66-70; discussion 70-1.</reference_text>
        <pubmed_id>7740336</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinorelbine</name>
        <accession>HMDB14505</accession>
      </metabolite>
      <reference>
        <reference_text>Seve P, Dumontet C: [Class III beta tubulin expression in nonsmall cell lung cancer].  Rev Mal Respir. 2010 Apr;27(4):383-6. Epub 2010 Mar 25.</reference_text>
        <pubmed_id>20403547</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Kurtzberg LS, Roth SD, Bagley RG, Rouleau C, Yao M, Crawford JL, Krumbholz RD, Schmid SM, Teicher BA: Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents. Cancer Chemother Pharmacol. 2009 Oct;64(5):1029-38. Epub 2009 Mar 10.</reference_text>
        <pubmed_id>19277662</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M: Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther. 2010 May;9(5):1339-48. Epub 2010 May 4.</reference_text>
        <pubmed_id>20442307</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Jordan MA, Kamath K: How do microtubule-targeted drugs work? An overview.  Curr Cancer Drug Targets. 2007 Dec;7(8):730-42.</reference_text>
        <pubmed_id>18220533</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Correia JJ: Effects of antimitotic agents on tubulin-nucleotide interactions.  Pharmacol Ther. 1991 Nov;52(2):127-47.</reference_text>
        <pubmed_id>1818332</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Jordan A, Hadfield JA, Lawrence NJ, McGown AT: Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998 Jul;18(4):259-96.</reference_text>
        <pubmed_id>9664292</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Islam MN, Iskander MN: Microtubulin binding sites as target for developing anticancer agents.  Mini Rev Med Chem. 2004 Dec;4(10):1077-104.</reference_text>
        <pubmed_id>15579115</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Gupta S, Bhattacharyya B: Antimicrotubular drugs binding to vinca domain of tubulin.  Mol Cell Biochem. 2003 Nov;253(1-2):41-7.</reference_text>
        <pubmed_id>14619954</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Podofilox</name>
        <accession>HMDB15310</accession>
      </metabolite>
      <reference>
        <reference_text>Wolff J, Knipling L, Cahnmann HJ, Palumbo G: Direct photoaffinity labeling of tubulin with colchicine.  Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2820-4.</reference_text>
        <pubmed_id>2011590</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Colchicine</name>
        <accession>HMDB15466</accession>
      </metabolite>
      <reference>
        <reference_text>Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ: Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005 Sep 15;11(18):6615-24.</reference_text>
        <pubmed_id>16166440</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Colchicine</name>
        <accession>HMDB15466</accession>
      </metabolite>
      <reference>
        <reference_text>Acharya BR, Choudhury D, Das A, Chakrabarti G: Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74.</reference_text>
        <pubmed_id>19527023</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Colchicine</name>
        <accession>HMDB15466</accession>
      </metabolite>
      <reference>
        <reference_text>Li CM, Lu Y, Ahn S, Narayanan R, Miller DD, Dalton JT: Competitive mass spectrometry binding assay for characterization of three binding sites of tubulin. J Mass Spectrom. 2010 Oct;45(10):1160-6.</reference_text>
        <pubmed_id>20814887</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Colchicine</name>
        <accession>HMDB15466</accession>
      </metabolite>
      <reference>
        <reference_text>Cerquaglia C, Diaco M, Nucera G, La Regina M, Montalto M, Manna R: Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy. 2005 Feb;4(1):117-24.</reference_text>
        <pubmed_id>15720245</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
